IsoRay, Inc has signed a distribution agreement with Inter V Medical of Montreal, Quebec, Canada. Inter V Medical will have exclusive rights to sell Cesium-131 Brachytherapy seeds in Canada which have been previously approved by Health Canada.
Inter V Medical has been bringing new medical technologies, including brachytherapy and related products, to the Canadian market for nearly twenty years.
Richard Wood, Inter V medical vice president of Business Development commented. “Having been in brachytherapy, we were able to see immediately the huge advantages to Cesium-131; in particular it’s short half life and higher dose rate. This should translate into lower cancer cell survival.”
Wood continue, “While Cesium-131 will be sold at a premium to other isotopes in Canada, nothing comes close to it in what it does for a man’s quality of life. We believe if this message is delivered clearly to the Canadian male population suffering with prostate cancer, many of those men will opt for Cesium-131 as their preferred choice of treatment. When they carry this message to their Doctors, then we will be there to insure that all Canadian specialists in Uro-Oncology and Radiation Oncology are aware of the many benefits of Cesium-131. We believe Cesium-131 has an even brighter future treating other types of cancer, namely lung, breast and neck. For all of these reasons, it was necessary to protect our position as the exclusive distributor for Canada.”
Inter V Medical brings to IsoRay Medical a team of nine dedicated sales professionals strategically placed across Canada.
Dwight Babcock, chairman and CEO stated. “We are very excited to partner with such an outstanding group as Inter V Medical in Canada. Inter V Medical has well established relationships with the physicians who are interested in incorporating Cesium-131 into their practices and will help expedite the penetration of the Canadian market. We will be partnering on all current and future IsoRay products.”
IsoRay through its subsidiary, IsoRay Medical, Inc, is the sole producer of the Cesium-131 brachytherapy seed.